AU2017262155B2 - Certain protein kinase inhibitors - Google Patents

Certain protein kinase inhibitors Download PDF

Info

Publication number
AU2017262155B2
AU2017262155B2 AU2017262155A AU2017262155A AU2017262155B2 AU 2017262155 B2 AU2017262155 B2 AU 2017262155B2 AU 2017262155 A AU2017262155 A AU 2017262155A AU 2017262155 A AU2017262155 A AU 2017262155A AU 2017262155 B2 AU2017262155 B2 AU 2017262155B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017262155A
Other languages
English (en)
Other versions
AU2017262155A1 (en
Inventor
Ling Chen
Zhifang Chen
Tongshuang Li
Min Lin
Yanxin Liu
Jing Sun
Rui Tan
Weibo Wang
Xianlong WANG
Lijun Yang
Xingdong ZHAO
Zuwen ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fochon Pharmaceuticals Ltd
Original Assignee
Fochon Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fochon Pharmaceuticals Ltd filed Critical Fochon Pharmaceuticals Ltd
Publication of AU2017262155A1 publication Critical patent/AU2017262155A1/en
Application granted granted Critical
Publication of AU2017262155B2 publication Critical patent/AU2017262155B2/en
Assigned to FOCHON PHARMACEUTICALS, LTD. reassignment FOCHON PHARMACEUTICALS, LTD. Request for Assignment Assignors: FOCHON PHARMACEUTICALS, LTD., SHANGHAI FOCHON PHARMACEUTICAL CO., LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2017262155A 2016-05-07 2017-05-05 Certain protein kinase inhibitors Active AU2017262155B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333165P 2016-05-07 2016-05-07
US62/333,165 2016-05-07
PCT/CN2017/083162 WO2017193872A1 (en) 2016-05-07 2017-05-05 Certain protein kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2017262155A1 AU2017262155A1 (en) 2018-12-06
AU2017262155B2 true AU2017262155B2 (en) 2021-03-11

Family

ID=60266275

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017262155A Active AU2017262155B2 (en) 2016-05-07 2017-05-05 Certain protein kinase inhibitors

Country Status (13)

Country Link
US (1) US10835535B2 (cg-RX-API-DMAC7.html)
EP (1) EP3452484B1 (cg-RX-API-DMAC7.html)
JP (1) JP6927548B2 (cg-RX-API-DMAC7.html)
KR (1) KR102374033B1 (cg-RX-API-DMAC7.html)
CN (1) CN109153686B (cg-RX-API-DMAC7.html)
AU (1) AU2017262155B2 (cg-RX-API-DMAC7.html)
DK (1) DK3452484T3 (cg-RX-API-DMAC7.html)
ES (1) ES2954148T3 (cg-RX-API-DMAC7.html)
MX (1) MX387648B (cg-RX-API-DMAC7.html)
RU (1) RU2738837C2 (cg-RX-API-DMAC7.html)
TW (1) TWI752026B (cg-RX-API-DMAC7.html)
WO (1) WO2017193872A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808238B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN116836177A (zh) * 2022-09-28 2023-10-03 锦州奥鸿药业有限责任公司 一种蛋白激酶抑制剂的枸橼酸盐、其晶型、制备方法和用途
WO2025085360A1 (en) 2023-10-16 2025-04-24 The Board Of Regents Of The University Of Oklahoma Heteroarotinoids and/or cdk4/6 inhibitors for treating human papillomavirus (hpv)-induced dysplasias, warts, and cancer in hpv-infected subjects
US20260209246A1 (en) * 2025-01-23 2026-07-23 Incyte Corporation Furanyl or thienyl pyrimidines as cdk4 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015180642A1 (en) * 2014-05-28 2015-12-03 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US6277985B1 (en) 1995-09-15 2001-08-21 Pharmacia & Upjohn Company Aminoaryl oxazolidinone N-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
EP1768967B1 (en) 2004-07-20 2009-04-22 Symed Labs Limited Novel intermediates for linezolid and related compounds
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
DE102007038251A1 (de) 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
SI2215094T1 (sl) 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
FR2988722B1 (fr) * 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015180642A1 (en) * 2014-05-28 2015-12-03 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors

Also Published As

Publication number Publication date
RU2738837C2 (ru) 2020-12-17
CN109153686B (zh) 2021-04-30
EP3452484A1 (en) 2019-03-13
JP2019516790A (ja) 2019-06-20
MX2018013573A (es) 2019-08-01
ES2954148T3 (es) 2023-11-20
ZA201808238B (en) 2022-10-26
WO2017193872A1 (en) 2017-11-16
RU2018143284A3 (cg-RX-API-DMAC7.html) 2020-07-31
KR102374033B1 (ko) 2022-03-14
AU2017262155A1 (en) 2018-12-06
MX387648B (es) 2025-03-18
BR112018072699A2 (pt) 2019-02-19
JP6927548B2 (ja) 2021-09-01
CN109153686A (zh) 2019-01-04
CA3023460A1 (en) 2017-11-16
RU2018143284A (ru) 2020-06-08
US10835535B2 (en) 2020-11-17
EP3452484B1 (en) 2023-07-05
US20190209566A1 (en) 2019-07-11
TW201805290A (zh) 2018-02-16
KR20190025545A (ko) 2019-03-11
DK3452484T3 (da) 2023-09-25
EP3452484A4 (en) 2019-10-09
TWI752026B (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
WO2022228387A1 (en) Compounds as parp inhibitors
EP3765462B1 (en) Substituted (2-azabicyclo [3.1.0] hexan-2-yl) pyrazolo [1, 5-a] pyrimidine and imidazo [1, 2-b] pyridazine compounds as trk kinases inhibitors
EP4110782A1 (en) Compounds as cdk2/4/6 inhibitors
WO2018127130A1 (en) Compounds as bcl-2-selective apoptosis-inducing agents
EP3452484B1 (en) Certain protein kinase inhibitors
WO2018192462A1 (en) Apoptosis-inducing agents
WO2017133701A1 (en) Certain protein kinase inhibitors
AU2019241260A1 (en) Macrocyclic compounds as TRK kinases inhibitors
AU2021268845A1 (en) Compounds as Bcl-2 inhibitors
WO2021047584A1 (en) SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS
WO2023231777A1 (en) Compounds as bcl-2 inhibitors
US10800785B2 (en) Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors
WO2022268065A1 (en) Compounds as erk inhibitors
CA3023460C (en) Cdk4/6 inhibitors for the treatment of hyper-proliferative diseases
WO2020063659A1 (en) Substituted [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
WO2020063860A1 (en) Naphthyridinone and pyridopyrimidinone compounds useful as kinases inhibitors
WO2024032755A1 (en) Compounds as bcl-2 inhibitors
BR112018072699B1 (pt) Compostos inibidores de proteína cinase, composição farmacêutica que os compreende e seus usos

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: FOCHON PHARMACEUTICALS, LTD.

Free format text: FORMER OWNER(S): SHANGHAI FOCHON PHARMACEUTICAL CO., LTD.; FOCHON PHARMACEUTICALS, LTD.